Compare · MYOV vs ROIV
MYOV vs ROIV
Side-by-side comparison of Myovant Sciences Ltd. (MYOV) and Roivant Sciences Ltd. (ROIV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MYOV and ROIV operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ROIV is the larger of the two at $26.60B, about 22.7x MYOV ($1.17B).
- ROIV has hit the wire 28 times in the past 4 weeks while MYOV has been quiet.
- ROIV has more recent analyst coverage (19 ratings vs 7 for MYOV).
- Company
- Myovant Sciences Ltd.
- Roivant Sciences Ltd.
- Price
- $26.99+0.00%
- $36.14-1.86%
- Market cap
- $1.17B
- $26.60B
- 1M return
- -
- -0.96%
- 1Y return
- -
- +141.50%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2016
- News (4w)
- 0
- 28
- Recent ratings
- 7
- 19
Myovant Sciences Ltd.
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of assisted reproduction and is under phase 2 clinical trial. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.
Roivant Sciences Ltd.
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Latest MYOV
- SEC Form 15-12G filed by Myovant Sciences Ltd.
- SEC Form EFFECT filed by Myovant Sciences Ltd.
- SEC Form EFFECT filed by Myovant Sciences Ltd.
- SEC Form 25-NSE filed by Myovant Sciences Ltd.
- SEC Form 4: Valente Nancy returned 3,673 shares to the company, closing all direct ownership in the company (withholding obligation)
- SEC Form 4: Potter Myrtle S returned 3,673 shares to the company, closing all direct ownership in the company to satisfy tax liability
- SEC Form 4: Merendino Lauren returned 169,538 shares to the company, closing all direct ownership in the company to satisfy withholding tax
- SEC Form S-8 POS filed by Myovant Sciences Ltd.
- SEC Form 4: Mehra Uneek returned 202,696 shares to the company, closing all direct ownership in the company (for tax liability)
- SEC Form S-8 POS filed by Myovant Sciences Ltd.
Latest ROIV
- Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
- Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
- Chief Accounting Officer Humes Jennifer covered exercise/tax liability with 3,880 shares, decreasing direct ownership by 4% to 106,419 units (SEC Form 4) (for tax liability)
- CFO Pulik Richard covered exercise/tax liability with 2,129 shares, decreasing direct ownership by 0.78% to 269,681 units (SEC Form 4) (withholding tax)
- Director Manchester Keith S was granted 5,054 shares, increasing direct ownership by 0.29% to 1,753,457 units (SEC Form 4)
- Director Gold Daniel Allen was granted 5,054 shares, increasing direct ownership by 0.06% to 8,965,815 units (SEC Form 4)
- Director Oren Ilan was granted 5,054 shares, increasing direct ownership by 4% to 123,680 units (SEC Form 4)
- Director Momtazee James C was granted 5,054 shares, increasing direct ownership by 5% to 111,959 units (SEC Form 4)
- Director Fitzgerald Meghan was granted 5,054 shares, increasing direct ownership by 14% to 41,162 units (SEC Form 4)
- Director Epperly Melissa B, was granted 5,054 shares, increasing direct ownership by 51% to 14,954 units (SEC Form 4)